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A
lthough in his recent editorial Atkinson (1)
made a persuasive argument to consider alter-
native trial designs for type 1 diabetes, we are in
disagreement with the suggestion that placebo-
controlled trials are no longer needed in studies evaluating
therapies to alter the natural history of type 1 diabetes in
recently diagnosed subjects.
Many of the frustrations about the pace of discovery felt
by patients, families, and researchers confuse the actual
facts about clinical trials. Although it is true that enroll-
ment in clinical trials overall is difﬁcult and hampers the
national imperative to translate basic science to clinical
care, clinical trials in new-onset type 1 diabetes have not
had problems with enrollment. For example, a current
placebo-controlled TrialNet study will be fully enrolled in
less than four months.
It is important for individuals who enroll in clinical trials
to understand that a clinical trial is an experiment—we do
not know whether or not the therapy will be helpful, in-
effective, or even harmful. The addition of a placebo arm is
the best way to ensure that this central hypothesis of
a clinical trial is rigorously tested. Non–placebo-controlled
trials may lead to therapeutic misconceptions; we do
patients and families no favors by implying clinical beneﬁt
even inadvertently.
Atkinson asserts that we have sufﬁcient information
about the natural history of insulin secretion after di-
agnosis to use this information as a standard historical
“control” group. Unfortunately, this is not entirely true.
There is signiﬁcant variation in the rate of fall of C-peptide
over time, and only a fraction of this variation is impacted
by known variables. The studies cited by Atkinson contain
approximately 100 placebo-treated patients, and those
used for proposed power calculations contain fewer than
30 placebo-treated patients. Short of a miracle therapy in
which all treated individuals had no fall in C-peptide over
time, comparing the decline in C-peptide from uncontrolled
trials with these published patients will not enable us to
reliably choose how to move forward with further de-
velopment of either single or combination therapy.
Most importantly, at this relative early stage of clinical
trials in type 1 diabetes, we must not allow our emotions to
get ahead of the science. Although recent results have been
extremely encouraging, only limited information about true
clinical beneﬁt and harms can be obtained from the relatively
small clinical trials reported to date (;60–200 patients).
Performing such trials without a control group provides
even less information for regulatory agencies and clinicians
alike and may hinder the development of new “standards
of care.”
Novel approaches such as adaptive trial design could be
particularly useful in the coming era of combination ther-
apies for type 1 diabetes, but abandoning placebo-controlled
studies moves us backward and not toward the future of
successful modulation of the autoimmune process in type
1d i a b e t e s .
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